Advertisement

Main Themes and Concluding Comments

  • J. Rick Turner
Chapter

Abstract

This book has provided an introductory overview of the immensely complex process of lifecycle drug development. Since various aspects of this process have been discussed individually in the preceding chapters, this final chapter takes a more global view. It brings together threads that have run throughout the individual chapters and presents an integrative summary of topics discussed to date. Following these summary discussions, several new topics are introduced.

Keywords

Drug Development Numerical Representation Precision Medicine Estimate Treatment Effect Drug Development Process 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Kalow W, 2005, Historical aspects of pharmacogenetics. In Kalow W, Meyer UA, Tyndale RF (Eds), Pharmacogenomics, 2nd Edition. Boca Raton: Taylor & Francis, 1–11.Google Scholar
  2. Fletcher RH, Fletcher SW, 2005, Clinical Epidemiology, 4th Edition. Philadelphia: Lippincott Williams & Wilkins.Google Scholar
  3. Primrose SB, Twyman RM, 2006, Genomics: Applications to Human Biology. Oxford: Blackwell Publishing.Google Scholar
  4. Holmes MR, Ramkissoon KR, Giddings MC, 2005, Proteomics and protein identification. In Baxevanis AD, Ouellette BFF (Eds), Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, 3rd Edition. Hoboken, NJ: Wiley-Interscience, 445–572.Google Scholar
  5. Soloviev M, Barry R, Terrett J, 2004, Chip-based proteomics technology. In Rapley F, Harbron S (Eds), Molecular Analysis and Genome Discovery. Hoboken, NJ: Wiley.Google Scholar
  6. Gad SC, 2006, Statistical and Experimental Design for Toxicologists and Pharmacologists, 4th Edition. Boca Raton: CRC Press.Google Scholar
  7. Machin D, Campbell MJ, 2005, Design of Studies for Medical Research. Chichester, UK: Wiley.CrossRefGoogle Scholar
  8. Piantadosi S, 2005, Clinical Trials: A Methodologic Perspective, 2nd Edition. Hoboken, NJ: Wiley.CrossRefGoogle Scholar
  9. Rothstein MA (Ed), 2003, Preface. Pharmacogenomics: Social, Ethical, and Clinical Dimensions. Hoboken, NJ: Wiley-LISS.Google Scholar
  10. Meyer UA, 2002, Introduction to pharmacogenomics: Promises, opportunities, and limitations. In Licinio J, Wong M-L (Eds), Pharmacogenomics: The Search for Individualized Therapies. Manheim, Germany: Wiley-VCH, 1–8.Google Scholar
  11. Cohen MR (Ed), 2007, Medication Errors, 2nd Edition. Washington, DC: American Pharmacists Association.Google Scholar
  12. Katz DL, 2001, Clinical Epidemiology and Evidence-based Medicine: Fundamental Principles of Clinical Reasoning and Research. Thousand Oaks: Sage Publications.Google Scholar
  13. Chow S-C, Liu J-P, 2004, Design and Analysis of Clinical Trials: Concepts and methodologies. Boca Raton: CRC/Taylor FrancisGoogle Scholar
  14. Derenzo E, Moss J, 2006, Writing Clinical Research Protocols: Ethical Considerations. San Diego: Elsevier.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Cardiac Safety Services QuintilesDurhamUSA

Personalised recommendations